A randomized double-blind controlled exploratory study comparing repeated administration of CS-8958 to oseltamivir phosphate in patients with influenza virus infection
Latest Information Update: 07 Jan 2022
Price :
$35 *
At a glance
- Drugs Laninamivir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 06 Jun 2016 New trial record